newsfilter
← Latest News
GlobeNewswire·

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling